Roger Adsett Sells 1,429 Shares of Insmed (NASDAQ:INSM) Stock

Insmed, Inc. (NASDAQ:INSM) COO Roger Adsett sold 1,429 shares of Insmed stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $173.33, for a total transaction of $247,688.57. Following the transaction, the chief operating officer directly owned 110,462 shares of the company’s stock, valued at $19,146,378.46. This represents a 1.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Roger Adsett also recently made the following trade(s):

• On Thursday, January 8th, Roger Adsett sold 2,059 shares of Insmed stock. The stock was sold at an average price of $174.17, for a total transaction of $358,616.03.
• On Wednesday, January 7th, Roger Adsett sold 802 shares of Insmed stock. The shares were sold at an average price of $175.07, for a total transaction of $140,406.14.

Insmed Price Performance

Shares of INSM traded down $5.73 on Thursday, hitting $170.27. The company’s stock had a trading volume of 2,588,589 shares, compared to its average volume of 2,142,398. The company has a market capitalization of $36.31 billion, a PE ratio of -27.51 and a beta of 1.08. The company has a debt-to-equity ratio of 0.59, a current ratio of 4.63 and a quick ratio of 4.34. Insmed, Inc. has a fifty-two week low of $60.40 and a fifty-two week high of $212.75. The company has a 50 day moving average price of $190.79 and a 200 day moving average price of $151.24.

Insmed (NASDAQ:INSM) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). Insmed had a negative net margin of 264.83% and a negative return on equity of 183.55%. The business had revenue of $142.34 million for the quarter, compared to analyst estimates of $114.33 million. During the same period in the prior year, the business earned ($1.27) earnings per share. The company’s revenue for the quarter was up 52.4% on a year-over-year basis. On average, research analysts anticipate that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Key Insmed News

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: High-profile media attention — Jim Cramer singled out Insmed as “worth keeping an eye on,” which can attract retail interest and trading volume. Read More.
• Neutral Sentiment: Public SEC disclosures: the insider sales were reported in Form 4 filings (transparent regulatory reporting), and insiders still retain large positions — meaning these may be planned sales rather than full exits. See aggregated reporting of recent insider transactions. Read More.
• Negative Sentiment: Large, concentrated insider selling — multiple senior executives (CEO William Lewis, CFO Sara Bonstein, COO Roger Adsett and other insiders) sold thousands of shares across Jan. 6–8. Such clustered sales by top management often spook investors and can pressure the stock. One recent block sale by insider Orlov (87,290 shares, ~$15.3M) is particularly large and notable. Read More.
• Negative Sentiment: Investor litigation risk — Pomerantz LLP announced an investigation into claims on behalf of Insmed investors, which raises legal/settlement risk and typically weighs on sentiment until resolved. Read More.

Hedge Funds Weigh In On Insmed

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Chung Wu Investment Group LLC acquired a new position in shares of Insmed in the 2nd quarter valued at $173,000. Resolute Capital Asset Partners LLC acquired a new stake in shares of Insmed during the second quarter worth $2,748,000. Caxton Associates LLP bought a new stake in Insmed in the first quarter valued at about $441,000. Assenagon Asset Management S.A. lifted its stake in Insmed by 84.5% in the second quarter. Assenagon Asset Management S.A. now owns 73,404 shares of the biopharmaceutical company’s stock valued at $7,387,000 after buying an additional 33,626 shares during the period. Finally, Public Employees Retirement System of Ohio acquired a new position in Insmed in the second quarter valued at about $5,578,000.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on INSM shares. Bank of America upped their price target on shares of Insmed from $142.00 to $187.00 and gave the stock a “buy” rating in a research report on Monday, October 27th. Wedbush set a $203.00 target price on shares of Insmed in a research note on Thursday, December 18th. Wolfe Research set a $167.00 price target on shares of Insmed and gave the company an “outperform” rating in a research note on Thursday, December 18th. Cowen set a $241.00 price target on shares of Insmed in a report on Thursday, December 18th. Finally, Morgan Stanley set a $157.00 price objective on shares of Insmed in a research report on Thursday. Two analysts have rated the stock with a Strong Buy rating, twenty have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Insmed currently has an average rating of “Moderate Buy” and an average price target of $205.64.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.